.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Teva
Merck
Queensland Health
Boehringer Ingelheim
Express Scripts
UBS
McKinsey
US Army
QuintilesIMS

Generated: February 17, 2018

DrugPatentWatch Database Preview

Patents Expiring in July 2026

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
NovartisVALTURNAaliskiren hemifumarate; valsartanTABLET;ORAL022217-002Sep 16, 2009DISCNNoNo➤ Sign Up➤ Sign UpY
NovartisVALTURNAaliskiren hemifumarate; valsartanTABLET;ORAL022217-001Sep 16, 2009DISCNNoNo➤ Sign Up➤ Sign UpY
Vertex Pharms IncKALYDECOivacaftorGRANULE;ORAL207925-002Mar 17, 2015RXYesYes➤ Sign Up➤ Sign UpMETHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
Vertex Pharms IncKALYDECOivacaftorGRANULE;ORAL207925-002Mar 17, 2015RXYesYes➤ Sign Up➤ Sign UpMETHOD OF TREATING CYSTIC FIBROSIS
Vertex PharmsKALYDECOivacaftorTABLET;ORAL203188-001Jan 31, 2012RXYesYes➤ Sign Up➤ Sign UpMETHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
Vertex Pharms IncKALYDECOivacaftorGRANULE;ORAL207925-001Mar 17, 2015RXYesNo➤ Sign Up➤ Sign UpMETHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
Vertex PharmsKALYDECOivacaftorTABLET;ORAL203188-001Jan 31, 2012RXYesYes➤ Sign Up➤ Sign UpMETHOD OF TREATING CYSTIC FIBROSIS
Vertex Pharms IncKALYDECOivacaftorGRANULE;ORAL207925-001Mar 17, 2015RXYesNo➤ Sign Up➤ Sign UpMETHOD OF TREATING CYSTIC FIBROSIS
Aerie Pharms IncRHOPRESSAnetarsudil dimesylateSOLUTION/DROPS;OPHTHALMIC208254-001Dec 18, 2017RXYesYes➤ Sign Up➤ Sign UpYYREDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Aerie Pharms IncRHOPRESSAnetarsudil dimesylateSOLUTION/DROPS;OPHTHALMIC208254-001Dec 18, 2017RXYesYes➤ Sign Up➤ Sign UpYYREDUCTION OF ELEVATED INTRAOCULAR PRESSURE
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Covington
Accenture
Farmers Insurance
Healthtrust
Argus Health
McKesson
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot